Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Uveoscleral outflow is a physiological pathway for the drainage of aqueous humor from the anterior chamber of the eye, distinct from the conventional trabecular meshwork route. Aqueous humor passes from the anterior chamber through spaces between longitudinal muscle bundles of the ciliary body into the suprachoroidal space, and then traverses through the sclera, exiting via perivascular spaces and other routes. This pathway is a therapeutic target for glaucoma, particularly with prostaglandin analogs that enhance outflow by modifying the ciliary muscle extracellular matrix. Uveoscleral outflow decreases with age and is modulated by ciliary muscle tone and certain pharmacological agents.
Modulation of ciliary muscle tone to alter the interstitial spaces and extracellular matrix, influencing aqueous humor flow through the uveoscleral pathway.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Uveoscleral Outflow.